Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.

Authors:
von Knebel Doeberitz N; Paech D; Sturm D; Pusch S; Turcan S and 1 more

Journal:
Int J Cancer

Publication Year: 2022

DOI:
10.1002/ijc.34131

PMCID:
PMC9474618

PMID:
35603902

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Int J Cancer

Abbreviation: Int J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Chronic acidosis rewires cancer cell metabolism through PPARα signaling.
Rolver MG; Holland LKK; Ponniah M and 11 more (2023) - Transparency Score: 4/6
A defect of amphiregulin release predicted longer survival independently of YAP expression in patie…
Maille E; Levallet J; Dubois F and 17 more (2022) - Transparency Score: 3/6
Agricultural activities and risk of central nervous system tumors among French farm managers: Resul…
Petit P; Gandon G; Chabardès S and 1 more (2022) - Transparency Score: 3/6
A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H and 3 more (2022) - Transparency Score: 3/6
A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia g…
Faber MT; Frederiksen K; Palefsky JM and 1 more (2022) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST Ownership: Yogen Saunthararajah—EpiDestiny. Income: None. Research support: none. Intellectual property: Yogen Saunthararajah—patents around tetrahydrouridine, decitabine and 5‐azacytidine (US 9259469 B2; US 9265785 B2; US 9895391 B2) and cancer differentiation therapy (US 9926316 B2). Stefan Pusch—eligible to royalties as co‐inventor of BAY1436032. The corresponding patents are under the administrative supervision of the DKFZ technology transfer office. All other authors declare no conflicts of interest."

Evidence found in paper:

"Funding information Deutsche Forschungsgemeinschaft, Grant/Award Number: 445704496; National Cancer Institute, Grant/Award Numbers: P30 CA043703, R21 CA263430, RO1 CA204373; National Heart, Lung and Blood Institute, Grant/Award Number: PO1 HL146372"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025